New method at the Danish Medicines Council gives Merck hope of a Danish breakthrough for its sclerosis treatment
German pharmaceutical company Merck has high hopes that a new method of evaluating treatments at the Danish Medicines Council, as well as new data, will pave the way for wider usage of sclerosis drug Mavenclad.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY CATHERINE BRETT
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.